Cellectar Biosciences Q2 net loss widens on higher R&D costs

Cellectar Biosciences

13/08/2026 12:24

Overview
US cancer drug developer's Q2 net loss widened yr/yr as R&D expenses increased
Cash and equivalents rose to $34 mln after May 2026 financing round

Outlook
Company expects cash balance to fund operations into Q2 2027

Result Drivers
R&D SPENDING - Higher research and development expenses driven by initiation of WM confirmatory iopofosine I 131 and CLR 125 TNBC studies
LOWER G&A COSTS - General and administrative expenses fell due to reduced commercialization efforts, professional fees, and lower personnel costs

Company press release: ID:nGNX2hjcn7

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.57
 
Q2 Net Loss
 
$6.90 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Cellectar Biosciences Inc is $10.00, about 284.6% above its August 12 closing price of $2.60

Reuters Recommended Reads
Aug 11 - Erasca Q2 net loss widens on higher R&D costs
Aug 12 - Kura Oncology Q2 product revenue rises 57% on KOMZIFTI uptake
Aug 11 - SELLAS Life Sciences Q2 net loss widens on higher expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)